

Indication	Target	Candidate	Research	Hit	Lead	Pre-clinic	Phase I	Phase II	Sponsor / Licensee	
PDAC CRC, GBM, Ewing Sarcoma, Melanoma	Neurotensin receptor	IPN-01087								
		3BP-227								
NN	FAP-2286	FAP-2286							3B Pharmaceuticals Europe	CLOVIS ONCOLOGY US, RoW (ex Europe)
Solid Tumors	Fibroblast Activation Protein α (FAP)	3B-401							3B Pharmaceuticals	
			3B-402							
Neuroendocrine Tumors	GIP receptor	Debio 0228								
CAIX Expressing Tumors	CAIX	NTA								
Solid Tumors	Undisclosed	NTB								
Solid Tumors	Undisclosed	NTC								
Solid Tumors	Undisclosed	3BP							3B Pharmaceuticals	
Solid Tumors	Undisclosed	3BP							3B Pharmaceuticals	
Solid Tumors	Undisclosed	3BP							3B Pharmaceuticals	

THERAPEUTIC RADIOPHARMACEUTICAL
 DISTINCT SPECT OR PET IMAGING AGENT

Indication	Target	Candidate	Research	Hit	Lead	Pre-clinic	Phase I	Phase II	Sponsor / Licensee	
PDAC CRC, GBM, Ewing Sarcoma, Melanoma	Neurotensin receptor	IPN-01087 3BP-227 NN								
Solid Tumors	Fibroblast Activation Protein α (FAP)	FAP-2286							 Europe	
Neuroendocrine Tumors	GIP receptor	3B-401 3B-402								
CAIX Expressing Tumors	CAIX	Debio 0228								
Solid Tumors	Undisclosed	NTA								
Solid Tumors	Undisclosed	NTB								
Solid Tumors	Undisclosed	NTC								
Solid Tumors	Undisclosed	3BP								
Solid Tumors	Undisclosed	3BP								
Solid Tumors	Undisclosed	3BP								

THERAPEUTIC RADIOPHARMACEUTICAL
 DISTINCT SPECT OR PET IMAGING AGENT